TSC-ASSOCIATED SEIZURE REDUCTION

EPIDIOLEX®
(cannabidiol)
significantly reduced the frequency of TSC-associated seizures by half

Reduction in monthly frequency of TSC-associated seizures

2x

GREATER REDUCTION

vs placebo

2x

GREATER REDUCTION

vs placebo

Results from the 16-week treatment period. Primary endpoint seizures included all countable TSC-associated seizures, including partial-onset seizures and generalized seizures (tonic-clonic, tonic, clonic, or atonic).

*The median percent reduction from baseline for patients living with TSC was 43% for patients receiving EPIDIOLEX 25 mg/kg/day, compared with 20% for patients receiving placebo (P<0.01).

Partial-onset seizures (focal) included simple partial seizures (focal motor seizure), complex partial seizures (focal impaired), and secondary generalized tonic-clonic seizures (focal to bilateral tonic-clonic).1

Patients at baseline2:

  • Had previously tried a median of 4 prior ASMs
  • Currently uncontrolled with a median of 3 current ASMs

89% of patients were taking ≥2 ASMs at baseline and still experiencing 57 TSC-associated seizures per 28 days.2

TSC-associated Seizure Frequency Reduction | Post Hoc Analysis Icon

The most commonly used concomitant ASMs were:

45% valproate|

33% vigabatrin|

29% levetiracetam|

27% clobazam

Reductions in TSC-associated seizure frequency were reported as early as Day 6 in a post hoc analysis of the TSC clinical trial.3

The recommended maintenance daily dosage for EPIDIOLEX is 25 mg/kg/day for patients living with TSC.

Patients with moderate to severe hepatic impairment require a dose adjustment.

TSC-ASSOCIATED PARTIAL-ONSET SEIZURES

EPIDIOLEX®
(cannabidiol)
reduced TSC-associated partial-onset seizure score by 46% in a prespecified exploratory analysis4

Reduction in monthly composite partial-onset seizure score

1.6x

GREATER REDUCTION

vs placebo

Composite score is a weighted average of the 3 types of partial-onset seizures included in the primary endpoint1,4,5:
  • Simple partial seizures
  • Complex partial seizures
  • Secondary generalized tonic-clonic seizures

1.6x

GREATER REDUCTION

vs placebo

Composite score is a weighted average of the 3 types of partial-onset seizures included in the primary endpoint1,4,5:
  • Simple partial seizures
  • Complex partial seizures
  • Secondary generalized tonic-clonic seizures

Results from the 16-week treatment period. Results of the composite seizure score were not controlled for multiplicity; therefore, P-values are not reported.2,4

RESPONDER RATES AND SEIZURE FREEDOM

More patients living with TSC achieved ≥50% and ≥75% reductions in TSC-associated seizures with EPIDIOLEX®
(cannabidiol)
than with placebo

Responder rates (≥50% and ≥75% reductions in TSC-associated seizures from baseline)6

Results from the 16-week treatment period.

More patients achieved freedom from TSC-associated seizures with EPIDIOLEX.

6%

EPIDIOLEX
25 mg/kg/day

0%

PLACEBO

Prespecified exploratory endpoint: Change in mean number of TSC-Associated seizure-free days4*

Baseline
(per 28 days)
Maintenance period
(per 28 days)
Percent increase
EPIDIOLEX
25 mg/kg/day
n=71
7.4 days 14.7 days 97%
PLACEBO
n=76
7 days 10.9 days 55%
EPIDIOLEX
25 mg/kg/day
n=71
PLACEBO
n=76
Baseline
(per 28 days)
7.4 days 7 days
Maintenance period
(per 28 days)
14.7 days 10.9 days
Percent increase 97% 55%

*Analysis was not controlled for multiplicity and is considered exploratory in nature.4

3-YEAR OPEN-LABEL EXTENSION

3-year sustained reduction of TSC-associated seizures7

Open-label extension: Reduction in monthly frequency of TSC-associated seizures7

Open-Label Extension Trial for EPIDIOLEX | A Line Chart for Percentage of Responders

WEEKS

Open-Label Extension Trial for EPIDIOLEX | A Vertical Chart for Percentage of Responders
Ongoing Open-Label Extension Trial | EPIDIOLEX Line Chart

Decreasing n-values reflect a combination of discontinuations and rolling entry into the open-label extension trial.7

  • Patients received treatment in the open-label extension for a maximum of 1 year, except in the United States and Poland, where patients could continue beyond 1 year7
  • The majority of those eligible transitioned to a commercially available product7
99% (n=199) of patients with TSC who completed the controlled trial elected to continue into the open-label extension.7

Adverse events:

  • The long-term safety profile of EPIDIOLEX®
    (cannabidiol)
    in this open-label extension trial was generally similar to that observed in the EPIDIOLEX clinical development program7
  • There was 1 death reported during the study, which was deemed unrelated to treatment by the investigator7
  • In the open-label extension trial, titration to doses over 25 mg/kg/day was permitted. At higher doses, an increase in adverse reactions was observed7